Applied DNA Sciences

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Applied DNA Sciences reports strong Q1 results and eyes revenue diversification

Applied DNA Sciences demonstrated robust revenue growth and operational improvements in Q1 2023, driven by key revenue streams and cost management.
While facing financial challenges and dependency on key projects for guidance, the company is strategically positioned for growth and innovation.
Opportunities in nucleic acid therapies, strategic partnerships, and revenue diversification present a promising outlook for Applied DNA Sciences.

Applied DNA Sciences adapts focus to genomics amid revenue challenges

Applied DNA Sciences faced revenue challenges in Q2 2023 but showcased resilience through strategic focus on pharma genomics testing and DNA tagging solutions.
The company's emphasis on efficiency in mRNA manufacturing and pursuit of acquisitions signal a proactive approach to enhancing market competitiveness and technological capabilities.
While financial challenges persist, opportunities in genetic testing and compliance solutions position Applied DNA Sciences for future growth and market leadership.

Applied DNA Sciences reports revenue decline and operational challenges

Applied DNA Sciences faced challenges in revenue decline and increased operating expenses in Q3 2023, leading to an operating loss and concerns about its financial sustainability.
Despite these challenges, the company demonstrated strengths in enhancing mRNA initiatives through the Spindle Biotech acquisition and Linea IVT platform, as well as continued growth in supply chain traceability.
Opportunities lie in expanding partnerships with evaluation customers, leveraging the Linea IVT platform's capabilities, and exploring new revenue streams in DNA tagging applications.

Applied DNA Sciences reports Q4 revenue decline, focuses on growth

Applied DNA Sciences faced a challenging quarter with declining revenues and operating losses, but maintained a focus on innovation and growth.
The company's strategic strengths lie in biotherapeutic manufacturing, successful acquisitions, and plans for revenue expansion through the Linea IVT platform.
However, challenges such as Nasdaq compliance issues and financial pressures require careful management and strategic decision-making.
Opportunities for revenue growth and market expansion exist through customer relationships, product development, and addressing regulatory requirements.

Applied DNA Sciences tackles financial challenges while eyeing revenue growth

Applied DNA Sciences faces challenges with declining revenues and profitability, necessitating a focus on cost management and revenue generation to improve financial health.
Despite financial pressures, the company's strategic strengths lie in innovative product development, quality control measures, and efforts to enhance operational efficiency.
Opportunities for revenue growth exist through the commercialization of Linea IVT platform, international expansion, and partnerships, signaling potential for market expansion and increased customer adoption.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment offers DNA detection via PCR to provide and develop clinical molecular diagnostics and genetic testing services. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Announces Closing of $4.2 Million Registered Direct Offering

Applied DNA Announces Closing of $4.2 Million Registered Direct Offering

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with an institutional investor, providing for the purchase and sale of 1,496,400 shares of common stock (or common stock equivalents) at a price of $2.80 per share, in a registered direct offering, resulting in total gross proceeds of approximately $4.2 million,

Applied DNA Announces Pricing of $4.2 Million Registered Direct Offering

STONY BROOK, N.Y. & ROME--(BUSINESS WIRE)---- $APDN #cancervaccine--First Published Study Demonstrates LinearDNA Pan-Cancer and Colon Cancer Neoantigen.

Applied DNA and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -231.58% and 2.62%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Applied DNA Sciences (APDN) Reports Q1 Loss, Lags Revenue Estimates

Applied DNA Sciences, Inc.'s (APDN) CEO James Hayward on Q1 2022 Results - Earnings Call Transcript

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--Applied DNA First Quarter Fiscal 2022 Financial Results Feature Record Quarterly Revenues

Applied DNA First Quarter Fiscal 2022 Financial Results Feature Record Quarterly Revenues

Applied DNA Sciences (APDN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Applied DNA Sciences (APDN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--Applied DNA to report FQ1'22 financial results after market close on February 10, 2022, and host an investor call at 4:30 pm ET.

Applied DNA Schedules Fiscal 2022 First Quarter Financial Results Conference Call and Webcast for Thursday, February 10, 2022

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--Applied DNA to Deploy Linea™ 1.0 COVID-19 Assay for Rapid Detection of New Omicron Subvariant BA.2

Applied DNA to Deploy Linea™ 1.0 COVID-19 Assay for Rapid Detection of New Omicron Subvariant BA.2

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--Applied DNA submits a request for EUA to FDA for Linea 2.0 Assay and Linea Collection Kit; prepares for nationwide service rollout upon authorization.

Applied DNA Submits Request for Emergency Use Authorization to FDA for Linea™ 2.0 COVID-19 Assay and Linea™ Unsupervised At-Home Sample Collection Kit

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--FQ1'22 COVID-19 Testing Levels Up Over 90% Compared to FQ4'21; Company Reports Further Strengthening in FQ2'22 to Date.

Applied DNA Announces Continued Momentum in COVID-19 Testing Demand

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--Applied DNA's ADCL receives conditional approval from NYSDOH for Linea 2.0 COVID-19 Assay; Intends to file near-term EUA for assay and at-home kit.

Applied DNA Receives New York State Department of Health Conditional Approval for Linea™ 2.0 COVID-19 Assay as Laboratory Developed Test

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #cottonprovenance--The power of DNA used to confirm cotton authenticity and provenance is now augmented with stable isotope analysis.

Applied DNA and Stratum Reservoir (Isotech) Sign Memorandum of Understanding to Leverage Isotopic Analysis for Enhanced DNA-Based Cotton Authenticity and Provenance

Applied DNA Sciences Inc (NASDAQ: APDN) reported a more than ninefold Y/Y increase in Q4 FY21 revenues, driven by the rise in clinical laboratory service revenues related to COVID-19 testing. For Q4, the firm reported $3.0 million in revenues, up from $314,000 a year ago, beating the consensus Wall Street estimate of $2.3 million.

Applied DNA Sciences' Q4 Revenues Skyrockets Buoyed By Momentum In COVID-19 Diagnostic Testing

Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -53.13% and 5.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q4 2021 Results - Earnings Call Transcript

Applied DNA Sciences (NASDAQ:APDN) reported its Q4 earnings results on Thursday, December 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Applied DNA Sciences: Q4 Earnings Insights

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--- FQ4 Revenues of $3.0 Million, Up 868% Over FQ4'20 and Up 79% Over FQ3'21; Record Full-Year Revenues of $9.0 Million, up 367% Over Fiscal 2020 -

Applied DNA Reports Fourth Quarter and Full Fiscal Year 2021 Financial Results, Continuing Momentum in Diagnostic Testing

Applied DNA Sciences (NASDAQ:APDN) is set to give its latest quarterly earnings report on Thursday, 2021-12-09. Here's what investors need to know before the announcement.

A Preview Of Applied DNA Sciences's Earnings

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #AAFA--Applied DNA brings certain of cotton genomics to determination of authenticity and provenance; files provisional patent for Egyptian cotton biomarker.

Applied DNA Advances Cotton Genomics-based Methodology for Determination of Authenticity and Provenance

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN--Applied DNA to report fourth quarter and full-year 2021 financial results after market close on December 9, 2021.

Applied DNA Schedules Fourth Quarter and Full Fiscal Year 2021 Financial Results Conference Call and Webcast for Thursday, December 9, 2021

The stock price of Applied DNA Sciences Inc (NASDAQ: APDN) increased by over 50% pre-market today. This is why it happened.

Applied DNA Sciences (APDN) Stock: Why The Price Is Surging Today

Applied DNA Sciences Inc (NASDAQ:APDN) plans to introduce its Linea 2.0 COVID-19 Assay for the SARS-CoV-2 E and N genes after submitting its validation data to the New York State Department of Health (NYSDOH) in the next few days. The Company also announced that its EUA-authorized Linea COVID-19 Assay Kit likely exhibits a unique double S-gene target failure specific to the Omicron variant.

Applied DNA Stock Surges On Launch Plans For Linea 2.0 COVID-19 Assay For Omicron Variant

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--Introduces Linea 2.0 COVID-19 Assay Kit for the detection of Omicron variant. 1.0 test impacted by Omicron; can be used as a reflex test for Omicron.

Applied DNA Announces Strategy to Address Omicron SARS-CoV-2 Variant, Introduces Linea™ 2.0 COVID-19 Assay Kit

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #CARTcell--Applied DNA subsidiary LineaRx receives repeat orders and secures new CRO customer for LinearDNA. Demand for therapeutic DNA is driving inquiries.

News for Applied DNA Sciences Stock (APDN)